First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027

TAIPEI and EPALINGES, Switzerland and PARIS, Nov. 18, 2026 /PRNewswire/ — Onward Therapeutics, Inc. ("Onward Therapeutics" or the "Company") today announced that it has closed its NT$900 million (approximately US$28 million) Series B financing. The round was raised in two closings, the second of which took place in October 2026. It is the Company’s first capital increase in Taiwan since it completed its share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Before the share exchange, the Company had raised a total of CHF 75.5 million (approximately US$90 million) in its previous rounds. Proceeds from the Series B will fund the Company’s clinical programs, the manufacturing of clinical supplies, and early-stage R&D.